Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422591 · ClinicalTrials.gov registry record · Phase 2
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT00422591: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00422591 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 175 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00422591, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find out if standard chemotherapy given with idarubicin and Cytarabine (ara-C) can help to control AML. Objectives: To determine the complete response (CR) rate, event-free survival (EFS) and overall survival (OS) of patients with newly diagnosed acute myeloid leukemia (AML) receiving standard combination chemotherapy with Idarubicin and cytarabine.
Interventions
- DRUG Cytarabine
- DRUG Idarubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2006-12 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422591
The ClinicalTrials.gov registry entry for NCT00422591 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT00422591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00422591 about?
NCT00422591 is a clinical study titled "Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)". The goal of this clinical research study is to find out if standard chemotherapy given with idarubicin and Cytarabine (ara-C) can help to control AML. Objectives: To determine the complete response (CR) rate, event-free survival (EFS) and overall survival (OS) of patients with newly diagnosed acut...
What is the current status of trial NCT00422591?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2006-12. Estimated completion is 2017-01.
What interventions are being tested in trial NCT00422591?
The interventions under investigation include: Cytarabine (DRUG), Idarubicin (DRUG).
Who is sponsoring clinical trial NCT00422591?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.